AdipoGen Life Sciences

Luteolin

CHF 20.00
In stock
AG-CN2-0098-M0055 mgCHF 20.00
AG-CN2-0098-M02525 mgCHF 60.00
More Information
Product Details
Synonyms 3',4',5,7-Tetrahydroxyflavone; Luteolol; BRN 0292084; C.I. Natural Yellow 2; Digitoflavone; Flacitran; Flavopurpol; Daphneflavonol; Argemexitin
Product Type Chemical
Properties
Formula

C15H10O6

MW 286.2
CAS 491-70-3
RTECS LK9275210
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance Yellow solid.
Solubility Soluble in DMSO, DMF, methanol or ethanol. Slightly soluble in water.
InChi Key IQPNAANSBPBGFQ-UHFFFAOYSA-N
Smiles OC1=CC(O)=C2C(=O)C=C(OC2=C1)C1=CC=C(O)C(O)=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Anticancer and antimetastatic agent that induces apoptosis and modulates autophagy. Shown to inhibits kinase signalling, including PKC(ε) and Src kinase, HDAC, Phosphatidylinositol 3-kinase (PI3K) / Akt and p90 ribosomal S6 kinase (RSK1/RSK2).
  • Topoisomerase I Inhibitor.
  • Anti-inflammatory agent that inhibits 15-Lipoxygenase (15-LOX) and IL-6 production.
  • Antioxidant. Free radical scavenger.
  • Antiadipogenic agent, that inhibits PPAR-γ, fatty acid synthase (FAS) and α-Glucosidase.
  • Neuroprotective. Monoamine transporter activator and inhibitor of phosphodiesterases 1-5 (PDE1-5).
  • Shown to selectively inhibits chymotrypsin-like and trypsin-like proteasome catalytic activity.
Product References
  1. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor: Y.T. Huang, et al.; Br. J. Pharmacol. 128, 999 (1999)
  2. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid: J.S. Kim, et al.; Biosci. Biotechnol. Biochem. 64, 2458 (2000)
  3. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I: A.R. Chowdhury, et al.; Biochem. J. 366, 653 (2002)
  4. Inhibition of matrix-proteases by polyphenols: Chemical insights for anti-inflammatory and anti-invasion drug design: L. Sartor, et al.; Biochem. Pharmacol. 64, 229 (2002)
  5. Luteolin inhibits the nuclear factor-kappa B transcriptional activity in Rat-1 fibroblasts: S.H. Kim, et al.; Biochem. Pharmacol. 66, 955 (2003)
  6. Inhibition of 15-lipoxygenases by flavonoids: Structure-activity relations and mode of action: C.D. Sadik, et al.; Biochem. Pharmacol. 65, 773 (2003)
  7. Induction of apoptosis by luteolin through cleavage of Bcl-2 family in human leukemia HL-60 cells: A.C. Cheng, et al.; Eur. J. Pharmacol. 509, 1 (2005)
  8. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells: J. Fang, et al.; Carcinogenesis 28, 713 (2007)
  9. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1: S. Jang, et al.; PNAS 105, 7534 (2008)
  10. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation: D.T. Coleman, et al.; Mol. Cancer Ther. 8, 214 (2009)
  11. Physicochemical properties and antioxidant activities of luteolin-phospholipid complex: K. Xu, et al.; Molecules 14, 3486 (2009)
  12. Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation: H.S. Park, et al.; Biofactors 35, 373 (2009)
  13. Functional activation of monoamine transporters by luteolin and apigenin isolated from the fruit of Perilla frutescens: G. Zhao, et al.; Neurochem. Int. 56, 168 (2010)
  14. Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells: Y.-X. Wu & X. Fang; Planta Med. 76, 128 (2010)
  15. Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia: M.C. Yu, et al.; Pulmon. Gastrointest. Urogen. Pharmacol. 627, 269 (2010)
  16. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer: S. Byun, et al.; Cancer Res. 70, 2415 (2010)
  17. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells: S. Attoub, et al.; Eur. J. Pharmacol. 651, 18 (2011)
  18. Autophagy inhibitor chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells: L. Verschooten, et al.; PLoS One 7, e48264
  19. Raf and PI3K are the molecular targets for the anti-metastatic effect of Luteolin: H.Y. Kim, et al.; Phytother. Res. 27, 1481 (2013)
  20. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1): K.M. Reipas, et al.; Oncotarget 4, 329 (2013)
  21. Flavonoids from Ericameria nauseosa inhibiting PI3K/AKT pathway in human melanoma cells: T. Hell, et al.; Biomed. Pharmacother. 156, 113754 (2022)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.